Brief: Darolutamide Gets EU Approval for Third Prostate Cancer Indication

Orion Oyj

21/07/2025 08:37

July 21 (Reuters) - Orion Oyj ORNBV.HE:

DAROLUTAMIDE RECEIVES EU APPROVAL IN THIRD INDICATION FOR PATIENTS WITH ADVANCED PROSTATE CANCER

APPROVAL BASED ON POSITIVE PHASE III ARANOTE TRIAL RESULTS

Source text: ID:nGNEb9hWs8

Further company coverage: ORNBV.HE

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))